Tempus AI has announced a new initiative with Bristol Myers Squibb that aims to leverage Artificial Intelligence (AI), multimodal real-world data and data science techniques to optimise clinical trial designs and enhance the Probability of Technical and Regulatory Success (PTRS) across 5 initial clinical trial programs.

With Lens, Tempus’ AI-enabled analytical platform, BMS and Tempus are applying insights from a vast library of de-identified multimodal records to optimise clinical research and strengthen PTRS across BMS’ development portfolio. This collaboration combines unprecedented scale of real-world data with emerging AI-techniques to pressure test assumptions, characterise complex patient populations, validate control group assumptions, and pinpoint the optimal patient segments most likely to benefit from investigational therapies.

This new initiative is supporting key assets in solid tumor oncology, including lung, colon, and prostate cancers. Beyond oncology, the collaboration extends into neuroscience to accelerate drug development in Alzheimer’s Disease (AD), demonstrating the versatility of the Tempus multimodal database across multiple therapeutic areas.

Ryan Fukushima, CEO, Data and Apps, Tempus, said, "Our collaboration with BMS aims to optimise clinical development by peering deeper into patient biology than ever before. Our multimodal data library allows us to connect the dots between clinical records and molecular subtypes. Together, we are doing more than just generating insights. We are uncovering the hidden biological signals of unmet patient need, which allows us to assess trial assumptions and stratify patient groups with unprecedented precision. We are moving past traditional approaches and creating a new level of data-driven confidence in the drug development process."

This initiative builds upon the existing work between Tempus and BMS, which includes the deployment of the Next Pathways program across 13 community-based health systems to address care gaps for patients with advanced Non-Small Cell Lung Cancer (aNSCLC).

Bryan Campbell, Senior Vice President, Drug Development Strategy and Innovation, Bristol Myers Squibb, said, “This collaboration is about improving the quality of decisions we make in development, where the impact is greatest. By combining Tempus’ multimodal real-world data capabilities with our development expertise, we can rigorously pressure-test trial assumptions, better understand patient heterogeneity, and design studies with a higher probability of technical and regulatory success. This is a critical step toward more disciplined, data-driven development with the goal of bringing life-changing medicines to patients faster.”